FLUKONATSOLI BORRELIOOSIN HOIDOSSA

[Bb]

Lähettäjä: Soijuv Lähetetty: 15.12.2004 14:42

Jokin aika sitten laitoin sivuillemme saksalaisen tutkimuksen hiivalääkkeenä käytetyn flukonatsolin (Diflucan) vaikutuksesta borrelioosiin. Nykyään tutkimuksen tehnyt lääkäri käyttää Diflucania 200 mg 50 pv:n ajan (tutkimuksessa 25 pv). Seuraavassa on myös amerikkalaisen lääkärin kommentti siihen miksi Diflucan saattaisi olla hyödyksi myös borrelioosin hoidossa - Bb on herkkä sytokromi P 450 entsyymien inhibiittoreille. Flukonatsoli saattaa olla tällainen inhibiittori.


Clinical effects of fluconazole in patients with neuroborreliosis.

Schardt FW.

Betriebsarztliche Untersuchungsstelle, Bayerische Julius-Maximilians-
Universitat, Wurzburg, Germany. Fritz.Schardt@m...

Eleven patients with neuro-borreliosis had been treated with 200 mg
fluconazole daily for 25 days after an unsuccessful therapy with
antibiotics. At the end of treatment eight patients had no
borreliosis symptoms and remained free of relapse in a follow-up
examination one year later. In the remaining four patients, symptoms
were considerably improved. At the end of therapy immune reactivity
(IgM+) disappeared in three patients. Since borrelia spp. are almost
exclusively localised intracellular, they may depend on certain
metabolites of their eucaryotic host cell. Inhibition of P450 and
other cytochromes by fluconazole may incapacitate Borrelia upon
longterm exposure.

PMID: 15337633 [PubMed - in process]
....................................................................

We believe that borrelia maybe susceptible to p450 inhibitors such as
HCQ and fluconazole. The later being safer and more effective.

Yes, diflucan is usually prescribed for yeast infections, however,
there's good evidence to suggest that borrelia are also vulnerable to
P450 inhibitors. Borrelia have only 1 P450 homologue enzyme,
putidaredoxin (PdR), and that would make it extremely susceptible to
an inhibitor of that enzyme. Fluconazole may just be that inhibitor.

Schardt's success in these patients is very significant.

Schardt is now recommending 50 days at 200 mg rather than only 25